Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.China Biopharmaceutical has completed the acquisition of all of the shares in RACP Pharmaceutical Holdings and its subsidiaries, including Shenyang Enshi Pharmaceuticals, for a total consideration of approximately $16 million.
Subscribe to our email newsletter
All required legal procedures with the relevant Chinese government regulatory and audit procedures have been completed and the title ownership of 100% of Enshi has been passed to China Biopharmaceuticals (CHBP).
“With 2005 revenue of $11.3 million and net income of $5.1 million, Enshi will have a positive impact on CHBP’s financial and market profile, and further demonstrates our strategy of growth through accretive, value-enhancing acquisitions,” said Chris Mao, CHBP CEO.
China Biopharmaceuticals is a research-driven pharmaceutical company dedicated to the discovery, development, manufacturing and marketing of small and large molecule pharmaceutical products, including medicines, vaccines, and active pharmaceutical ingredients for various categories of diseases. It is a US public company with operating subsidiaries and senior management based in China.
Shenyang Enshi Pharmaceuticals, meanwhile, is based in Shenyang, China, and is engaged in the manufacturing and distribution of pharmaceutical products.